Moderna announces global regulatory submissions for its respiratory syncytial virus (RSV) vaccine, mRNA-1345


5 July 2023 - Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia.

Moderna today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease and acute respiratory disease in adults aged 60 years or older.

Read Moderna press release

Michael Wonder

Posted by:

Michael Wonder